Guilherme Godoy, MD, MPH, presented “Urologic Debate Part 1: MRI vs. Molecular Markers – Which One Should I Use? MRI Perspective” virtually during the Innovations in Urologic Practice 2020 virtual conference in September 2020.
How to cite: Godoy, Guilherme. “Urologic Debate Part 1: MRI vs. Molecular Markers – Which One Should I Use? MRI Perspective” September 26th, 2020. Accessed Dec 2024. https://grandroundsinurology.com/urologic-debate-part-1-mri-vs-molecular-markers-which-one-should-i-use-mri-perspective/
Summary:
In the first part of this urologic debate, Guilherme Godoy, MD, MPH, Assistant Professor of Urology and Urology Oncology at Baylor College of Medicine in Houston, Texas, argues for multiparametric MRI (mpMRI) as the better diagnostic tool for finding prostate cancer as compared to molecular markers. He observes that while there are many different commercial markers available to aid decision-making before diagnosis, at initial diagnosis, and after treatment, mpMRI can help in all three of these prostate cancer management spaces. Dr. Godoy also argues that while molecular tests may inform risk, a biopsy preceded by MRI will still be necessary, and that biopsy can be improved and optimized by mpMRI. He then discusses different techniques and equipment that can be used with mpMRI, how to interpret and report the results from mpMRI, and the trial evidence for mpMRI’s effectiveness. Dr. Godoy concludes that mpMRI functions as “the ideal biomarker,” as it increases accuracy and decreases the number of biopsies and helps to optimize care after cancer diagnosis.
About the Innovations in Urologic Practice 2020 virtual conference:
Presented by co-chairs Mohit Khera, MD, MBA, MPH, and Michael Coburn, MD, FACS, the Innovations in Urologic Practice conference provides a detailed review and commentary on multiple genitourinary and urologic diseases. Among the featured oncological topics are bladder cancer and immunotherapies, as well as upper tract cancer management, prostate cancer, including state-of-the-art imaging, focal therapy, and MRI. Experts also discuss new tools and techniques for nephrectomy and treating advanced renal cell carcinoma. In terms of general urological approaches, conference also include pelvic reconstruction and trauma, men’s health topics like male infertility and sexual dysfunction, and ways to diagnose and treat infections in the urology patient. Dr. Godoy presented this talk virtually at this year’s conference.
ABOUT THE AUTHOR
Guilherme Godoy, MD, MS, serves as assistant professor of urology at the Baylor College of Medicine (BCM) in Houston, Texas. He joined the faculty of the Scott Department of Urology at BCM in 2012 and has been the chief of the urology service at Ben Taub General Hospital (Harris Health System), since 2017.
Dr. Godoy earned his medical degree from Fundacao Universitaria do ABC in Sao Paulo, Brazil. His training includes an internship and residency in urology at Santa Casa De Sao Paulo in Vila Buarque, Brazil, and a fellowship in urologic oncology at BCM. Dr. Godoy has also completed urologic oncology fellowship training at Vancouver General Hospital, New York University, and Memorial Sloan-Kettering Cancer Center. He earned his MS in clinical investigations at BCM and has remained active in clinical research, translational studies, and clinical trials, mostly focused on prostate, urothelial (upper and lower urinary tract), and testicular cancers.
Dr. Godoy’s expertise includes early diagnosis, minimally invasive approaches (endoscopic and robotic), utilization of molecular and genetic tools for personalized decision-making, management of hereditary cancers, and surgical management of complex/large genitourinary (GU) tumors. His clinical areas of interest include adrenal and kidney tumors, urothelial cancers (upper and lower urinary tract including ureter, renal pelvis, bladder, and urethra), prostate cancer, penile cancer, and testicular and paratesticular cancers. Dr. Godoy also specializes in the utilization of intestinal segments for urinary tract reconstructions, and coordination of multidisciplinary approaches to manage complex intra-abdominal, retroperitoneal, and pelvic tumors. Dr. Godoy is responsible for and moderates the GU Tumor Board Meetings at Baylor St. Luke’s Medical Center as well as the St. Luke’s International GU Tumor Board Meetings.